1. Vietnam Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Domesco Medical Import-Export JSC

Domesco Medical Import-Export JSC

HHOSE:DMC
55,600.00
VND
-400.00
(-0.71%)
2.05TMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
41,165.95
45,097.81
35,534.72
37,065.97
38,576.11
39,884.53
42,283.26
41,809.96
43,147.26
45,863.61
49,500.64
54,695.24
59,529.75
- -
Basic EPS, GAAP
3,096.06
3,183.68
3,603.65
4,851.1
5,979.76
6,587.63
6,698.86
5,169.83
4,586.63
5,761.31
5,279.19
5,837.07
5,712.99
- -
Free Cash Flow per Basic Share
570.05
2,918.19
4,369.2
3,546.53
8,692.79
772.62
3,198.44
-1,701.18
4,501.65
7,576.83
4,077.79
-746.53
3,589.59
- -
Dividend per Share
1,123.24
573.74
1,384.63
1,538.48
2,000
2,500
2,500
2,500
2,500
2,500
2,500
2,500
2,500
- -
Book Value per Share
18,097.79
20,785.75
22,843.81
25,444.8
27,436.67
32,525.84
36,059.89
37,876.99
39,335.77
42,027.56
43,784.17
46,434.94
48,614
48,250.66
Tangible Book Value per Share
16,603.66
19,291.23
21,362.13
24,015.26
26,043.05
31,147.68
34,675.53
36,530.34
38,022.49
40,687.7
42,468.31
44,895.19
47,141.36
46,783.43
Basic Weighted Avg Shares
35
33
35
35
35
35
35
35
35
35
35
35
35
38
Sales/Revenue/Turnover
1,429,609
1,486,060
1,234,031
1,287,207
1,339,651
1,385,088
1,468,390
1,451,954
1,498,395
1,592,727
1,719,032
1,899,427
2,067,317
- -
Operating Margin (%)
9.35
10.88
14.92
16.06
17.94
19.05
18.18
13.99
12.44
14.72
10.67
11.9
10.68
- -
Depreciation Expense
30,701
34,993
34,834
31,845
30,285
29,456
28,550
25,845
24,146
19,700
18,987
17,329
19,361
- -
Net Income, GAAP
107,520
132,322
141,559
168,466
207,662
228,772
232,635
179,535
159,282
200,076
183,333
202,707
198,398
- -
Effective Tax Rate (%)
20.25
21.56
22.74
20.02
20.03
20.03
20.03
20.05
20.04
20.03
20
20.02
20.05
- -
Profit Margin (%)
7.52
8.9
11.47
13.09
15.5
16.52
15.84
12.37
10.63
12.56
10.66
10.67
9.6
- -
Working Capital
323,834
428,327
526,266
643,244
727,355
897,201
1,018,973
1,093,512
1,166,023
1,220,280
1,343,193
1,299,667
1,467,931
1,462,310
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
630,565
721,846
793,318
883,633
952,806
1,129,540
1,252,269
1,315,372
1,366,031
1,459,510
1,520,513
1,612,568
1,688,241
1,675,623
Return on Invested Capital (%)
14.74
16.95
18.34
-19.7
21.92
21.11
18.77
13.67
11.69
13.87
11.81
12.61
11.69
- -
Return on Capital (%)
16.15
18.72
18.69
20.29
22.62
21.74
19.42
14.01
11.88
14.46
12.3
12.94
12.03
- -
Return on Common Equity (%)
17.94
15.54
16.52
20.09
22.62
21.97
19.53
13.98
11.88
14.16
12.3
12.94
12.02
- -

Capital Structure

VND

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
35
Market Capitalization
2,073,230
2,045,448
2,048,920

Working Capital

VND

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,694,905
1,730,583
1,757,565
Cash, Cash Equivalents & STI
566,842
579,613
585,144
Accounts Receivable, Net
554,088
548,984
566,456
Inventories
521,235
553,869
573,957
Total Current Liabilities
226,974
204,904
295,255
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

VND

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.93%
5.12%
4.69%
Free Cash Flow
-84.57%
-208.33%
-580.84%
Net Income, GAAP
4.57%
2.88%
-2.13%
Sales/Revenue/Turnover
5.34%
7.35%
8.84%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

VND

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
419,177
461,665
448,077
570,508
1,899,427
2025
469,129
510,288
- -
559,004
2,067,317
2026
519,590
519,177
- -
- -
- -

Quarterly Earnings Per Share

VND

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,179.48
1,500
802
1,882
5,837.07
2025
1,354.23
776
- -
2,237
5,712.99
2026
1,524.12
1,384
- -
- -
- -

Quarterly Dividends Per Share

VND

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2,500
2025
- -
- -
- -
- -
2,500
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Huong Giang Thi Luong
Full Time Employees
912
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Cao Lanh Vietnam
IPO Date
Dec 25, 2006
Website
domesco.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Domesco Medical Import-Export Joint Stock Corporation manufactures, markets, and distributes pharmaceutical products, dietary supplements, and medical equipment in Vietnam and internationally. The company provides a broad range of pharmaceutical formulations across key therapeutic areas, including cardiovascular and antihypertensive agents; antibiotics, antibacterial, and antifungal medications; analgesics, antipyretics, and nonsteroidal anti-inflammatory drugs; gastrointestinal, digestive, and metabolic treatments; respiratory, cough, and antihistamine preparations; central nervous system and neurological medicines; and vitamins, minerals, and nutritional tonics. In addition to pharmaceutical manufacturing, the company produces traditional herbal medicines, functional health supplements, and purified bottled water, while engaging in the import, export, and distribution of active pharmaceutical ingredients, diagnostic supplies, hospital consumables, and medical devices. Domesco distributes its products through domestic hospital and clinic bidding channels (ETC), retail pharmacy chains, and independent drugstores across Vietnam, as well as export channels across Asia, Africa, and the Americas. Founded in 1989 and headquartered in Cao Lanh, Dong Thap Province, Vietnam, Domesco operates as a subsidiary of CFR International SpA, an affiliate of Abbott Laboratories. In recent developments, the company has expanded its manufacturing capacity and upgraded its production facilities to meet stringent WHO-GMP, GLP, and GSP standards, deepened operational integration and technology transfer initiatives with Abbott Laboratories to advance high-value prescription lines for chronic diseases, optimized its supply chain and distribution reach across modern pharmacy retail networks, and expanded its therapeutic pipeline with new generic and biosimilar bioequivalent product registrations in regional emerging markets.